Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson’s disease

Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson’s disease

Abstract Background Parkinson’s disease (PD) is characterized by intracellular alpha-synuclein (α-syn) inclusions, progressive death of dopaminergic neurons in the substantia nigra pars compacta (SNpc), and activation of the innate and adaptive immune systems. Disruption of immune signaling between...

Full description

Bibliographic Details
Main Authors:	Gregory P. Williams, Aubrey M. Schonhoff, Asta Jurkuvenaite, Aaron D. Thome, David G. Standaert, Ashley S. Harms
Format:	Article
Language:	English
Published:	BMC 2018-08-01
Series:	Journal of Neuroinflammation
Subjects:	Parkinson’s disease (PD) Class II transactivator (CIITA) α-Synuclein Major histocompatibility complex II (MHCII) Neuroinflammation Neurodegeneration
Online Access:	http://link.springer.com/article/10.1186/s12974-018-1286-2

Similar Items

α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration
by: Ashley S. Harms, et al.
Published: (2017-11-01)

Amelogenin Downregulates Interferon Gamma-Induced Major Histocompatibility Complex Class II Expression Through Suppression of Euchromatin Formation in the Class II Transactivator Promoter IV Region in Macrophages
by: Karen Yotsumoto, et al.
Published: (2020-04-01)

Dynamic Regulation of the Class II Transactivator by Posttranslational Modifications
by: Morgan, Julie E
Published: (2015)

Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to α-synuclein-induced dopaminergic neurodegeneration
by: Itzia Jimenez-Ferrer, et al.
Published: (2017-10-01)

Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration
by: Megan F. Duffy, et al.
Published: (2018-05-01)

Microglia Response During Parkinson’s Disease: Alpha-Synuclein Intervention
by: Sara A. Ferreira, et al.
Published: (2018-08-01)

Enrichment and Quantification of Epitope-specific CD4+ T Lymphocytes using Ferromagnetic Iron-gold and Nickel Nanowires
by: Daniel E. Shore, et al.
Published: (2018-10-01)

Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation
by: Changyoun Kim, et al.
Published: (2018-08-01)

Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity
by: Matthew J. Benskey, et al.
Published: (2018-02-01)

Interactions between Calcium and Alpha-Synuclein in Neurodegeneration
by: Alex Rcom-H'cheo-Gauthier, et al.
Published: (2014-08-01)

Temporal Evolution of Inflammation and Neurodegeneration With Alpha-Synuclein Propagation in Parkinson's Disease Mouse Model
by: Thuy Thi Lai, et al.
Published: (2021-10-01)

Expression regulation of major histocompatibility complex (MHC) class I and class II encoding genes
by: Peter J van den Elsen, et al.
Published: (2011-10-01)

Distinct Molecular Mechanisms of Altered HLA Class II Expression in Malignant Melanoma
by: Stefanie Meyer, et al.
Published: (2021-08-01)

Interferon‐γ‐induced HLA Class II expression on endothelial cells is decreased by inhibition of mTOR and HMG‐CoA reductase
by: Akihiro Maenaka, et al.
Published: (2020-05-01)

Motor neuron loss and neuroinflammation in a model of α-synuclein-induced neurodegeneration
by: Zachary A. Sorrentino, et al.
Published: (2018-12-01)

Unraveling the molecular mechanisms of the class II transactivator, CIITA in skeletal muscle
by: Londhe, Priya V.
Published: (2013)

Modeling Parkinson’s Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers
by: Laura Boi, et al.
Published: (2020-11-01)

Avaliação do fator CIITA como potencial adjuvante molecular para vacinas e imunoterapias
by: Mariana de Lucena Palma
Published: (2015)

Avaliação do fator CIITA como potencial adjuvante molecular para vacinas e imunoterapias
by: Palma, Mariana de Lucena
Published: (2015)

α-Synuclein and Polyunsaturated Fatty Acids: Molecular Basis of the Interaction and Implication in Neurodegeneration
by: Chiara Fecchio, et al.
Published: (2018-06-01)

CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches
by: Elise Ramia, et al.
Published: (2019-03-01)

Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines
by: Accolla Roberto S, et al.
Published: (2012-07-01)

Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice
by: Kathryn P. MacPherson, et al.
Published: (2017-06-01)

Cholesterol lowering drug may influence cellular immune response by altering MHC II function[S]
by: Koushik Roy, et al.
Published: (2013-11-01)

The Close Encounter Between Alpha-Synuclein and Mitochondria
by: Mattia Vicario, et al.
Published: (2018-06-01)

CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine
by: Roberto S. Accolla, et al.
Published: (2019-07-01)

Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson’s Disease
by: Maria Angela Samis Zella, et al.
Published: (2019-01-01)

Editorial: The Protein Alpha-Synuclein: Its Normal Role (in Neurons) and Its Role in Disease
by: Ruth G. Perez
Published: (2020-02-01)

The MHC Class II Transactivator CIITA: Not (Quite) the Odd-One-Out Anymore among NLR Proteins
by: Jorge Alfonso León Machado, et al.
Published: (2021-01-01)

Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson’s Disease
by: Antonella Cardinale, et al.
Published: (2021-06-01)

Characterization of MHCII-Glycoantigen Presentation and T-cell Recognition in Human Volunteers
by: Neaga, Andreea
Published: (2008)

New Perspectives on Roles of Alpha-Synuclein in Parkinson’s Disease
by: Guoxin Zhang, et al.
Published: (2018-11-01)

Hepcidin-to-Ferritin Ratio Is Decreased in Astrocytes With Extracellular Alpha-Synuclein and Iron Exposure
by: Juntao Cui, et al.
Published: (2020-03-01)

Neuronal MHC-I expression and its implications in synaptic function, axonal regeneration and Parkinson’s and other brain diseases
by: Carolina eCebrián, et al.
Published: (2014-10-01)

Tripartite Motif 22 and Class II Transactivator Restriction Factors: Unveiling Their Concerted Action against Retroviruses
by: Greta Forlani, et al.
Published: (2017-10-01)

Interferon Regulatory Factors 1 and 2 Play Different Roles in MHC II Expression Mediated by CIITA in Grass Carp, Ctenopharyngodon idella
by: Xiao-Bing Lu, et al.
Published: (2019-05-01)

Boosting the MHC class II-restricted tumor antigen presentation to CD4+ T helper cells: a critical issue for triggering protective immunity and re-orienting the tumor microenvironment toward an anti-tumor state
by: Roberto eAccolla, et al.
Published: (2014-02-01)

The Prion-Like Spreading of Alpha-Synuclein in Parkinson’s Disease: Update on Models and Hypotheses
by: Asad Jan, et al.
Published: (2021-08-01)

Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease
by: Scarlet eGallegos, et al.
Published: (2015-03-01)

The Epigenetic Regulation of Cytokine Inducible Mammalian Transcription by the 26S Proteasome
by: Koues, Olivia I
Published: (2009)